Press Release

3 weeks ago

Egle Therapeutics to Present New Preclinical Data EGL-003, a Novel IL-2 Mutein for Selective Expansion of Tregs to Restore Immune Balance with Best-in-class Potential, at EULAR 2025 Congress

Paris, France, June 10th 2025 – Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, today announced a poster presentation at…

1 month ago

Egle Therapeutics to Present Clinical Trial Progress Poster on Phase I/II EGL-121 Study for EGL-001 at 2025 ASCO Annual Meeting

Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, today announced a poster presentation at the upcoming 2025 American Society of…

2 months ago

Egle Therapeutics to highlight novel preclinical findings for regulatory T cells targeting programs EGL-001 and EGL-002 with poster presentations at the 2025 AACR Annual Meeting

Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, will present two posters at the American Association for Cancer Research Annual…

4 months ago

Egle Therapeutics receives €9.3 Million in State Funding Under the “Innovations in Biotherapies and Bioproduction” Call for Projects from France 2030

Egle Therapeutics receives significant non-dilutive funding to accelerate the clinical development of its lead immuno-oncology therapeutic candidate, EGL-001, as part of the “Innovations in Biotherapies and Bioproduction” call for projects…

6 months ago

EGLE Therapeutics Strengthens its Executive Leadership team with the Appointment of Christophe Quéva, Ph.D, as Chief Executive Officer

Paris, France, January 13th, 2025 – Egle Therapeutics, a clinical-stage biotechnology company advancing the next generation of regulatory T cell (Treg)-focused therapies for oncology and autoimmune diseases, today announced the…

8 months ago

Egle Therapeutics to share preclinical efficacy data for EGL-001, a CTLA-4/CD25 antagonist fusion protein at the Society for Immunotherapy of Cancer Meeting

Egle Therapeutics, a biotechnology company focused on advancing the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, will present at the Society for Immunotherapy of Cancer Meeting…

10 months ago

EGLE Therapeutics Strengthens its Board of Directors with the Appointment of Michel Detheux, Ph.D, as Independent Chairman Board Member, and with the Appointment of Mojgan Hossein-Nia, Ph.D. as Board member representative of Takeda Ventures

EGLE Therapeutics Strengthens its Board of Directors with the Appointment of Michel Detheux, Ph.D, as Independent Chairman Board Member, and with the Appointment of Mojgan Hossein-Nia, Ph.D. as Board member…

12 months ago

Egle Therapeutics to share preclinical data for its first autoimmune disease program, EGL-003, with an oral presentation at the 2024 Promise of Interleukin-2 Therapy Meeting

Egle Therapeutics, a biotechnology company focused on advancing the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, will deliver an oral presentation at The Promise of Interleukin-2…

1 year ago

EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member

EGLE Therapeutics, a clinical-stage biotechnology company uniquely positioned to advance the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, announced today the appointment of Pejvack Motlagh MD,…